{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:37:14Z","timestamp":1784302634021,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Pemphigoid is a rare autoimmune disorder that may be drug-induced. This study aims to investigate the potential association between pemphigoid and quinolone using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports were analyzed using disproportionality methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). Subgroup analyses were performed by age, sex, and reporter type. An interaction analysis integrating published literature on quinolone-associated pemphigoid (QAP) was conducted to assess consistency in reporting disproportionality, demographics, latency, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 183 reports of quinolone-associated pemphigoid were identified. Ofloxacin accounted for the largest proportion of cases (47.0%), followed by ciprofloxacin (26.2%) and levofloxacin (23.0%). Significant disproportionality signals were detected for ofloxacin (ROR\u00a0=\u00a02.75), ciprofloxacin (ROR\u00a0=\u00a02.31), levofloxacin (ROR\u00a0=\u00a02.53). A remarkably high signal was also noted for norfloxacin (ROR\u00a0=\u00a025.14); however, this requires extremely cautious interpretation due to the very small number of cases (n=3). Most pemphigoid events occurred within 30 days of quinolone initiation, indicating a short latency pattern consistent with immune-mediated blistering reactions. Subgroup analyses revealed differential reporting patterns by age and sex. Furthermore, the interaction analysis with published literature corroborated the FAERS findings, demonstrating consistent patterns in demographic susceptibility (predominantly elderly and female), short latency, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates that several quinolone antibiotics are associated with an increased reporting frequency of pemphigoid in FAERS. The early onset and consistency across data sources support quinolone-associated pemphigoid as a clinically meaningful immune-related adverse drug reaction, underscoring the importance of early clinical recognition and monitoring during the initial phase of quinolone therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1808910","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:09:45Z","timestamp":1776330585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pemphigoid associated with quinolone antibiotics: a real-world pharmacovigilance study of the FDA adverse event reporting system and literature-based evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Integrated Traditional Chinese and Western Medicine Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Integrated Traditional Chinese and Western Medicine Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integrated Traditional Chinese and Western Medicine Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirou","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases and College of Pharmaceutical Sciences, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Integrated Traditional Chinese and Western Medicine Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integrated Traditional Chinese and Western Medicine Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01444-9","article-title":"A narrative review of pemphigoid diseases: Bridging associations, comorbidities, and management","volume":"15","author":"Myers","year":"2025","journal-title":"Dermatol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43556-025-00272-9","article-title":"Autoimmune bullous diseases: Pathogenesis and clinical management","volume":"6","author":"Feng","year":"2025","journal-title":"Mol BioMed"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.017","article-title":"Immunoglobulin M pemphigoid","volume":"85","author":"Boch","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00925-z","article-title":"Clinical outcomes and prognostic factors in bullous pemphigoid patients: A 15-year review in China","volume":"26","author":"Cao","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: A systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17107","article-title":"Incidence of pemphigoid diseases in northern Germany in 2016 - first data from the schleswig-holstein registry of autoimmune bullous diseases","volume":"35","author":"van Beek","year":"2021","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15046","article-title":"Autoimmune bullous dermatoses","volume":"21","author":"Holtsche","year":"2023","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.a","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: A nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: A population-based case-control study","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4270","article-title":"Gliptin-induced bullous pemphigoid: Withdrawal of gliptin allows for faster control of the disease","volume":"32","author":"Prugnit-Rouanet","year":"2022","journal-title":"Eur J Dermatol EJD"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-263285","article-title":"Remote presentation of nivolumab-induced bullous pemphigoid in hepatocellular carcinoma","volume":"18","author":"Yoo","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093026","article-title":"Cutaneous adverse events following nemolizumab administration: A review","volume":"14","author":"Mima","year":"2025","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15638","article-title":"Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis","volume":"23","author":"Pruessmann","year":"2025","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"B16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: A systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-021-00625-4","article-title":"DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: A pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020","volume":"22","author":"Jedlowski","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: Trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"de Nicolas-Ruanes","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S401663","article-title":"Quinolone antibiotics: Resistance and therapy","volume":"16","author":"Tang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237153","article-title":"Biological effects of quinolones: A family of broad-spectrum antimicrobial agents","volume":"26","author":"Millanao","year":"2021","journal-title":"Mol Basel Switz"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2021.035","article-title":"Fluoroquinolone antibiotics and adverse events","volume":"44","author":"Baggio","year":"2021","journal-title":"Aust Prescr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1527051","article-title":"Toxic epidermal necrolysis induced by moxifloxacin and exacerbated by clindamycin in an elderly patient: A case report","volume":"12","author":"Wang","year":"2025","journal-title":"Front Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.938476","article-title":"Levofloxacin-associated bullous pemphigoid in a hemodialysis patient after kidney transplant failure","volume":"23","author":"Miao","year":"2022","journal-title":"Am J Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1456","article-title":"Evaluation of anticancer therapy-related dermatologic adverse events: Insights from food and drug administration\u2019s adverse event reporting system dataset","volume":"91","author":"Salah","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"Tyagi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: Data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3186328","article-title":"HLA association with drug-induced adverse reactions","volume":"2017","author":"Fan","year":"2017","journal-title":"J Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1991.tb03867.x","article-title":"Pemphigus and bullous pemphigoid due to drugs","volume":"30","author":"Ruocco","year":"1991","journal-title":"Int J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731774","article-title":"Case report: A rare case of pembrolizumab-induced bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Nat Rev Dis Primer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: A review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1521697","article-title":"Linear IgA bullous dermatosis secondary to drugs: A real-world pharmacovigilance study of the FDA adverse event reporting system","volume":"12","author":"Yang","year":"2025","journal-title":"Front Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14456","article-title":"Alogliptin-induced bullous pemphigoid associated with HLA-DQB1*03:01: a case report","volume":"58","author":"Takata","year":"2019","journal-title":"Int J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2513989122","article-title":"HLA-DQB1*03:01 strongly affects age of onset of type 1 narcolepsy independently of DQA1 and ethnicity","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830863","article-title":"Emerging role of dipeptidyl peptidase-4 in autoimmune disease","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02279","article-title":"Sex hormones in acquired immunity and autoimmune disease","volume":"9","author":"Moulton","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01636.x","article-title":"Case of drug-induced bullous pemphigoid by levofloxacin","volume":"39","author":"Ma","year":"2012","journal-title":"J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1808910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:41:22Z","timestamp":1776346882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1808910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1808910"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1808910","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1808910"}}